NEWS
Another Takeda/Shire R&D exec jumps ship as Pharvaris nabs Peng Lu as its new CMO
| FierceBiotech

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed […]

Onvansertib Triplet Shows Promise in KRAS-Mutant Metastatic Colorectal Cancer
| Targeted Oncology

Patients with metastatic colorectal cancer (mCRC) treated with the combination of the investigational polo-like kinase 1 inhibitor, onvansertib, plus FOLFIRI (Irinotecan, Fluorouracil [5-FU], and folinic acid [leucovorin]), and bevacizumab (Avastin) had a 100% clinical benefit rate at 8 weeks by radiographic response in a phase Ib study presented at the 2020 Gastrointestinal Cancers Symposium. Data […]

Makers of novel cell/gene therapy say off-the-shelf approach only way to solve pricing woes

Innovative treatments have turned the tables somewhat in the battle against cancer but one stumbling block appears to be pricing. CAR-T cell therapy can cost more than $1.5 million including the $475,000 cost of the drug (in this case, Kymriah from Novartis). “We are seeing that price is becoming a barrier because if you can imagine, hundreds of thousands of […]